Gilead Sciences Inc. urged the Federal Circuit on Thursday to nix a Merck & Co. subsidiary’s bid for the full court to review a panel decision that wiped out a $2.5 billion verdict in a patent dispute, calling the Merck unit’s “attacks” on the panel’s ruling “an exercise in selective omission”…

Read this piece in its entirety at Law360.